Engineered immune cells for relapsed or refractory B-cell leukemia and lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment using your own immune cells that are modified to find and kill cancer cells in the blood or lymph nodes. It's for people whose leukemia or lymphoma has come back or did not go away after previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your cancer must be a type of B-cell acute lymphoblastic leukemia or B-cell lymphoblastic lymphoma that has returned or is not responding to treatment.
- You must have tested positive for a protein called BAFF-R on your cancer cells.
- You must have already tried a CD19-targeted therapy (like blinatumomab or CAR T cells) and it didn't work, or you are not eligible for it.
- You need to be in generally good health, with adequate kidney, liver, and heart function.
- You must not have had a stem cell transplant in the last 100 days, and you must not be taking immunosuppressive drugs (except for low-dose steroids).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a new type of immune-cell therapy (CAR T cells) that targets BAFF-R to treat certain relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). It aims to see if the treatment is safe and can shrink lymphoma in people who have tried prior therapies.
This trial tests a new kind of cell therapy where your own immune cells are turned into cancer-fighting cells (CAR-T cells) that target a protein called CD19 or BAFF-R on your B-cell leukemia or lymphoma cells. It is for people whose cancer has not gotten better with standard treatments or has come back.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BAFFR on B-cell blood cancers. The goal is to see if it can shrink tumors when given after a short chemotherapy course to prepare the body.
This trial tests a new type of immunotherapy called BAFF-R CAR-T cells for people with B-cell lymphoma that has come back or not responded to treatment, and whose cancer cells do not have the CD19 protein. The treatment uses your own immune cells, modified to target and kill the lymphoma cells.
This trial tests a new CAR-T cell treatment that targets a protein called BAFFR on cancer cells. It is for people with B-cell lymphoma that has come back or not responded to previous treatments.
This trial tests a new treatment called BAFF CAR-T cells (LMY-920) for people with certain types of lymphoma or multiple myeloma that have come back or not responded to previous treatments. The therapy uses your own immune cells, modified to attack cancer cells, and may offer a new option when standard treatments have not worked.
Hear when a new Recurrent B Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.